Some cancer vaccines, such as mRNA-based vaccines, can be personalized and custom-made for each patient. Personalized vaccines—while promising—also have challenges such as cost and long production times. However, a cancer vaccine that could be used as a potential off-the-shelf treatment for certain patients that share specific mutations is an intriguing possibility. The off-the-shelf vaccine could be manufactured in batches and given to patients with minimal delay. It also would be cheaper to produce.
Colorectal and pancreatic cancers—the second and third leading causes of cancer death, respectively—often have mutations in the KRAS protein. Now, a new vaccine shows encouraging early results as a potential off-the-shelf treatment for patients with pancreatic or colorectal cancer, according to a study co-led by researchers at Memorial Sloan Kettering Cancer Center (MSK).
The vaccine being tested here, ELI-002 2P, is described to enhance “lymph node delivery and immune response using amphiphile modification of G12D and G12R mutant KRAS (mKRAS) peptides (Amph-Peptides-2P) together with CpG oligonucleotide adjuvant (Amph-CpG-7909).”
Leave a reply